Table 1.

Baseline characteristics by treatment arm

	Bevacizumab (N=189)	Standard (N=170)	Total (N=359)
Molecular subgroup
Differentiated	36 (19.0%)	37 (21.8%)	73 (20.3%)
Immunoreactive	69 (36.5%)	53 (31.2%)	122 (34.0%)
Mesenchymal	37 (19.6%)	31 (18.2%)	68 (18.9%)
Proliferative	47 (24.9%)	49 (28.8%)	96 (26.7%)
Age (years) at randomization
Mean (SD)	58.1 (11.0)	57.4 (11.2)	57.8 (11.1)
Range	(26.0–80.0)	(21.0–80.0)	(21.0–80.0)
Race
White	189 (100.0%)	167 (98.2%)	356 (99.2%)
Asian	0 (0.0%)	3 (1.8%)	3 (0.8%)
ECOG score
0	77 (40.7%)	78 (45.9%)	155 (43.2%)
1	93 (49.2%)	83 (48.8%)	176 (49.0%)
2	19 (10.1%)	9 (5.3%)	28 (7.8%)
Origin of cancer
Ovary	169 (89.4%)	150 (88.2%)	319 (88.9%)
Fallopian tube	7 (3.7%)	7 (4.1%)	14 (3.9%)
Primary peritoneum	12 (6.3%)	12 (7.1%)	24 (6.7%)
Multiple sites	1 (0.5%)	1 (0.6%)	2 (0.6%)
Histology
Serous	150 (79.4%)	127 (74.7%)	277 (77.2%)
Clear cell	7 (3.7%)	7 (4.1%)	14 (3.9%)
Endometrioid	4 (2.1%)	6 (3.5%)	10 (2.8%)
Mucinous	3 (1.6%)	2 (1.2%)	5 (1.4%)
Mixed	15 (7.9%)	21 (12.4%)	36 (10.0%)
Other	10 (5.3%)	7 (4.1%)	17 (4.7%)
FIGO stage
I/IIA	14 (7.4%)	12 (7.1%)	26 (7.2%)
IIB/IIC	12 (6.3%)	11 (6.5%)	23 (6.4%)
III	134 (70.9%)	117 (68.8%)	251 (69.9%)
IV	29 (15.3%)	30 (17.6%)	59 (16.4%)
Outcome of surgery
Optimal	145 (76.7%)	129 (75.9%)	274 (76.3%)
Sub-Optimal	43 (22.8%)	40 (23.5%)	83 (23.1%)
missing	1 (0.5%)	1 (0.6%)	2 (0.6%)
High-risk of progression*
No	130 (68.8%)	110 (64.7%)	240 (66.9%)
Yes	59 (31.2%)	60 (35.3%)	119 (33.1%)
Grade
1 or 2	46 (24.5%)	28 (16.8%)	74 (20.8%)
3	142 (75.5%)	139 (83.2%)	281 (79.2%)
Missing	1	3	4

^*High risk of progression: suboptimal debulked stage III, inoperable Stage III, all stage IV patients.